Biomarkers of Bone Resorption in Metastatic Prostate Cancer
Completed
- Conditions
- Metastatic Prostate Cancer
- Registration Number
- NCT01233557
- Lead Sponsor
- University of Aberdeen
- Brief Summary
Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness. Changes in these biomarkers will be correlated with the patient's treatment with antiandrogen therapy and bisphosphonates and the response and/or progression of their cancer. It is hoped that serial measurement of these biomarkers may allow therapeutic monitoring in the future with successful individualisation of bisphosphonate therapy for metastatic prostate cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 40
Inclusion Criteria
- prostate cancer with bone metastases
- hormone sensitive
Exclusion Criteria
- inadequate renal function
- ongoing dental problems
- previous bisphosphonate therapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Aberdeen Royal Infirmary
🇬🇧Aberdeen, United Kingdom